Michael Brener, MD
Cardiovascular Disease · New York, NYNPI 1992075451
Payments from drug & device makers
What this record shows
This record is dominated by grants: $125,000 of the $146,096 with a category attached, or 85.6%. Edwards Lifesciences accounts for 70.2% of it on its own, with 22 other manufacturers making up the rest. Reporting peaked in 2024 at $59,860 and has fallen 96.5% since, to $2,125 in 2025. Among cardiovascular disease clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 147 payments — averaging $993.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Edwards Lifesciences$103K
- Merck$25K
- Abiomed$9K
- Ancora Heart, Inc.$3K
- Medtronic$2K
- Abbott$2K
- plus $3K from 17 others
What the payments were for
- Grants$125,00086%
- Travel & lodging$12,6909%
- Food & beverage$7,6505%
- Education$7561%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Edwards Lifesciences | 51 | $102,501 |
| Merck | 1 | $25,000 |
| Abiomed | 9 | $9,023 |
| Ancora Heart, Inc. | 2 | $3,352 |
| Medtronic | 20 | $1,825 |
| Abbott | 16 | $1,574 |
| AstraZeneca | 8 | $771 |
| Boston Scientific | 5 | $403 |
| Astellas Pharma US Inc | 3 | $280 |
| Heartflow, Inc. | 7 | $247 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 4 | $188 |
| Chiesi USA, Inc. | 5 | $167 |
| Johnson & Johnson | 1 | $125 |
| Pfizer | 1 | $121 |
| Cardiovascular Systems Inc. | 1 | $120 |
| Cathworks, Inc. | 1 | $84 |
| Novartis | 3 | $64 |
| Boehringer Ingelheim | 4 | $64 |
| Penumbra, Inc. | 1 | $63 |
| Livanova USA, Inc. | 1 | $50 |
| Teleflex LLC | 1 | $38 |
| E.r. Squibb & Sons, L.L.C. | 1 | $21 |
| Sanofi-aventis U.S. LLC | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Impella$8,812
- AccuCinch$3,352
- SAPIEN 3 Ultra RESILIA$1,179
- BRILINTA$640
- ONYX FRONTIER$514
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT$459
- COREVALVE EVOLUT R$387
- OPTIS$257
- CARDIOMEMS$186
- HeartMate 3 Left Ventricular Assist Device$166
- HeartMate 3 Left Ventricular Dev$159
- AVVIGO Guidance System$150
- FFRangio$146
- MitraClip$145
- XARELTO$125
- ELIQUIS$121
- Diamondback Coronary$120
- WATCHMAN Access System$115
How this compares
$146,096 in reported general payments places this provider in the 95th percentile of 2,302 cardiovascular disease providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other cardiovascular disease in New York
- Roger HajjarNew York$5.2M
- Gregg StoneNew York$2M
- Philippe GenereuxNew York$1.3M
- Adam RosenbluthNew York$1.1M
- Megha PrasadNew York$813K
- Eyal HerzogNew York$645K
- Nisha JhalaniNew York$443K
- Roxana MehranNew York$432K
- Howard WeintraubNew York$328K
- Anuradha Lala-TrindadeNew York$324K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.